-
Shenge Bushen Capsule Approved for Marketing by China NMPA
2022-12-29
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Shenge Bushen Capsule of Xinjiang Huachun Biological Pharmaceutical Co., Ltd was approved for marketing by China NMPA.
-
Qijiao Tiaojing Granule Approved for Marketing by China NMPA
2022-12-28
Recently, the new traditional Chinese medicine (TCM) compound preparation Qijiao Tiaojing Granule of Hunan Anbang Pharmaceutical Co., Ltd. was approved for marketing by China NMPA.
-
NMPA Holds Meeting to Promote PIC/S Accession
2023-07-29
On July 27, the Department of Drug Regulation of the NMPA holds a meeting in Kunming, Yunnan province to promote accession to the Pharmaceutical Inspection Co-operation Scheme(PIC/S).
-
Equecabtagene Autoleucel Injection Approved with Conditions by China NMPA
2023-06-30
Recently, the Equecabtagene Autoleucel injection(Chinese trade name: 福可苏) of Nanjing IASO Biotechnology is approved with conditions through the priority review and approval procedure by China NMPA.
-
Telpegfilgrastim Injection Approved for Marketing by China NMPA
2023-06-30
Recently, the Telpegfilgrastim injection (Chinese trade name: 珮金) of Xiamen Amoytop Biotech Co., Ltd. is approved for marketing by China NMPA.
-
Pegmolesatide Injection Approved for Marketing by China NMPA
2023-06-30
Recently, the Category 1 innovative drug Pegmolesatide Injection (Chinese trade name: 圣罗莱) of Jiangsu Hansoh Pharmaceutical Group Company Limited is approved by China NMPA.
